Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial @BloodPortfolio https://t.co/QlYJMQXlLZ

(1/10) How do diverse leukemia mutations converge on the same molecular program? In our new study @CellCellPress,the @RibackLab and @Goodell_Lab show that disparate mutations rewire shared protein networks to form nuclear condensates called coordinating bodies (C-bodies).🫧

@DraMartinezLago @myESMO @ESMO_Open @GrupoTTD @Erman_Akkus @OncoAlert @colontown @FightCRC @marklewismd @oncodaily @Larvol @OncBrothers @mtmdphd @RenoHemonc @SuyogCancer @GlopesMd We also addressed this🙋🏻‍♂️in this editorial at @NatureMedicine. bTMB ≠ tTMB It’s a whole different issue on how bad TMB is as a marker for immunotherapy for patients with colorectal cancer. However, even if you are going to use it, don’t in these post EGFR⛔️cases. @OncoAlert

CONGRESS | #IACH | PRESENTATION @Dr_AmerZeidan @YaleMed discusses the current menin inhibitor landscape for the treatment of NPM1m or KMT2Ar AML. He provides an overview of clinical trial data for revumenib, ziftomenib, bleximenib and enzomenib monotherapy and combination

New online! Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia

“garbage in, garbage out”: last week, Nature Methods published an article ( https://t.co/9fPO608NvR) comparing the deep learning models trained on scRNA-seq (single-cell transcriptomes) which were published in recent years — GENEFORMER, scGPT, scBERT, scFoundation, and others.

#IntheSpotlight A FABulous Couple: Adding PHENotype to GENotype Improves HMA/VEN Response Prediction in AML https://t.co/PqCzQD264b

Everyone working in a STEM field should read this - ‘writing is thinking’ https://t.co/pps0zyCURe

We are excited to share our work on "closing the loop" 🔄 - a framework enabling single-cell foundation models (scFMs) to learn from experimental validation and dramatically improve their predictive accuracy! (1/n)

Excellent example of the core issue I was trying to get at wrt "virtual cells" - optimizing a prediction objective will not necessarily provide an accurate representation of physical or biological phenomena. It's extremely important to be very clear about this. 1/

Clu+ HSCs represent myeloid/platelet-biased HSCs that expand with age, whereas Clu– youthful HSCs become underrepresented with age. https://t.co/KOuunvdCCM #hematopoiesisandstemcells

🚨New paper on theories of ageing I discuss the major mechanistic theories of ageing in light of recent findings as well as the fundamental nature of the ageing process. Theoretical work is more important than ever in biology, including in ageing. https://t.co/JG7XLI6QFS

New research shows that heat application, not cold, enhances recovery from muscle damage https://t.co/5Y8vdbwDqB

Still digesting all the data from #ASCO25. Wanted to share my thoughts on a topic I found particularly fascinating: the timing of checkpoint inhibitor infusions. I'm no expert in chronobiology, but the data presented seem compelling and sparks a lot of questions.

This was an amazing effort and practice changing study for LGL leukemia - cyclophosphamide is superior to MTX with respect to ORR with comparable safety - took 10 years to accrue but shows can do RCT in rare hem diseases #EHA25 #EHA2025

Over the last 2 weeks, I took a deep dive into Evo 2, Arc's Genomic Foundation model. But, I couldn't find a crisp primer on Evo 2 that covered the decisions for the ML architecture, the inference-time scaling results or the mechanistic interpretability results. So, I wrote one!

There are traditionally two types of research: problem-driven research and method-driven research. As we’ve seen with large language models and now AlphaEvolve, it should be very clear now that total method-driven research is a huge opportunity. Problem-driven research is nice

Delighted to share our study out in @CellStemCell today from the dream team @PapaemmanuilLab @iannisaifantis1 @AkEisfeld @landau_lab! We profiled IDH-mutated AML patients to define how IDH and co-mutations shape the disease at baseline and responses to IDH-inhibitors. 🧵👇

Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring |American Journal of Hematology | Blood Research Journal | Wiley Online Library

A number of people have asked me why we titled our recent paper "On the Biology of a Large Language Model". Why call it "biology"?